Skip to content
GLP-1 Savers

Research & guides

Semaglutide vs Tirzepatide: Comparing Cost and Evidence

Compare semaglutide and tirzepatide trial results, formulation differences and full ongoing costs with your prescriber's treatment plan in mind.

By Grant Ashford, Founder & Pricing Editor
What's in this guide

Trial results and program prices answer different questions. Your prescriber should help choose an appropriate medicine and formulation; then compare the full ongoing cost of that treatment. A lower advertised figure does not promise a particular weight-loss result or establish that a compounded product is equivalent to the medicine studied.

What the trials actually show

In the STEP-1 trial, once-weekly semaglutide produced roughly 15% average body-weight loss over 68 weeks1. In SURMOUNT-1, tirzepatide reached up to about 21% at its highest dose2. And in a head-to-head diabetes trial, SURPASS-2, tirzepatide beat semaglutide on weight and A1C reduction3. These are trial averages, not predictions for an individual patient. STEP-1 and SURMOUNT-1 are separate trials; their headline percentages are not a head-to-head comparison. SURPASS-2 studied people with type 2 diabetes, so its comparison also needs that population context.

The price half

Compare the full cost at the same prescribed dose, route and supply length, including required care fees. Our semaglutide price ladder and tirzepatide price ladder show advertised offers and their conditions. Programs handle the gap between the two molecules differently: yourEra states one price per molecule at every dose, while HealthRX prices each molecule separately across rolling, three-month and twelve-month plans. The Trellis Vitality pricing review provides an example of separate molecule prices within one program; confirm the applicable current plan rather than assuming its lowest figure is your maintenance cost.

Effect per dollar: how to decide

I would separate three decisions:

  • Ask your prescriber which treatment fits your medical history, goals and tolerability.
  • Compare that treatment's ongoing dose and formulation costs, rather than multiplying trial-average weight loss by a program's starting price.
  • If switching becomes appropriate, check the new prescription, pharmacy and price terms before assuming one account gives you the same service at the same bill.

Don't let a teaser distort the comparison

Compare the ongoing flat prices, not intro rates. A tirzepatide that advertises a cheap first month and then triples can look competitive with semaglutide when it isn't. We break the pattern down in how to spot a GLP-1 teaser-rate trap. The honest comparison uses the month-twelve price for both.

Verify before you optimize

A pharmacy license does not by itself establish whether a particular compounded prescription meets the applicable requirements. Compounded drugs are not FDA-approved and FDA does not verify their safety, effectiveness or quality before marketing4. Review the current compounding rules as well as the pharmacy — see is cheap compounded GLP-1 safe?. And if you have insurance, price the brand-name versions too in compounded vs brand-name GLP-1 before defaulting to cash.

The value verdict

There is no single price-per-result winner for every patient. Use your actual prescription and full recurring bill to compare offers. Our Trimi Health pricing review is one program-specific example of terms to read, and the compare tools help compare published prices. Neither chooses a medicine or predicts your response.

If you're comparing the brand-name products specifically

The trial results above do not establish equivalence for compounded products. Price comparisons must keep approved brands and compounded formulations distinct. If you're insured and choosing between the actual FDA-approved brands, the calculation runs differently — see Wegovy vs Zepbound: what's actually different for the head-to-head trial data and how each brand's approved uses have diverged. And semaglutide and tirzepatide aren't the only two molecules in this class worth pricing out — the older, once-daily liraglutide is still a real option for some budgets; see semaglutide vs liraglutide: is the older, cheaper GLP-1 worth it?

This piece sits in our research index alongside every other sourced explainer we publish — the trials, the compounding rules and the pricing mechanics, grouped by the question each one answers.

On the brand side, each product publishes its own self-pay ladder rather than one price: Ozempic, Wegovy and Zepbound all advertise a starting-dose figure that changes once you titrate up.

Frequently asked questions

Which loses more weight, semaglutide or tirzepatide?

SURMOUNT-1 reported up to about 21% average weight loss and STEP-1 roughly 15%, but these were separate trials. SURPASS-2 directly compared the medicines in people with type 2 diabetes. None of these averages predicts an individual response or establishes equivalence for compounded products.

Which GLP-1 is cheaper?

Some programs advertise lower semaglutide prices, but your cost depends on formulation, prescribed dose, required fees, supply and coverage. Compare actual ongoing bills for clinically appropriate options, including current brand cash offers.

Which is the better value?

There is no universal price-per-result winner. Discuss appropriate treatment with your prescriber, then compare the complete ongoing costs and program terms. Starting prices and trial-average results cannot establish which option will give you better value.

References

  1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/35658024/
  3. Frías JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/34170647/
  4. U.S. Food and Drug Administration (2026). Compounding and the FDA: Questions and Answers. FDA.gov. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.